Evidence map›Paper›PMID 41003763›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2026

Head to head comparison of [

Wolfgang Roll, Panayiotis Hadjitheodorou, Emmanouil Alevroudis, Kyriaki Kyrou, Giorgos Adamou, Andreas Fesas, Björn Wängler, Carmen Wängler, Ralf Schirrmacher, Mohammad R Pourkhessalian and 3 more

Abstract readComparative Study
PubMed Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. High-contrast somatostatin receptor imaging of meningiomas with [¹⁸F]SiTATE PET/CT.European journal of nuclear medicine and molecular imaging · 2026
    Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Wolfgang Roll *Department of Nuclear Medicine, University Hospital Münster, Münster, Germany.
Panayiotis Hadjitheodorou *Department of Nuclear Medicine, German Oncology Center, Limassol, Cyprus.ORCID 0000-0001-7736-5831
Emmanouil AlevroudisDepartment of Nuclear Medicine, German Oncology Center, Limassol, Cyprus.
Kyriaki KyrouDepartment of Nuclear Medicine, German Oncology Center, Limassol, Cyprus.
Giorgos AdamouDepartment of Nuclear Medicine, German Oncology Center, Limassol, Cyprus.
Andreas FesasDepartment of Nuclear Medicine, German Oncology Center, Limassol, Cyprus.
Björn WänglerClinic of Radiology and Nuclear Medicine, Molecular Imaging and Radiochemistry, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
Carmen WänglerClinic of Radiology and Nuclear Medicine, Biomedical Chemistry, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
Ralf SchirrmacherDepartment of Oncology, Division of Oncological Imaging, University of Alberta, Edmonton, Canada.
Mohammad R PourkhessalianDepartment of Nuclear Medicine, German Oncology Center, Limassol, Cyprus.
Charalambia KalogirouDepartment of Nuclear Medicine, German Oncology Center, Limassol, Cyprus.
Ioannis TsechelidisDepartment of Nuclear Medicine, German Oncology Center, Limassol, Cyprus.
Alexis VrachimisDepartment of Nuclear Medicine, German Oncology Center, Limassol, Cyprus. alexis.vrachimis@goc.com.cy.ORCID 0000-0001-5316-7697

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn neuroendocrine tumors molecular imaging methods play a key role, either targeting the somatostatin receptor or catecholamine pathways. [

methods38 patients with suspected neuroendocrine tumors were prospectively included. All patients underwent both [

results22 of 38 patients did not show [

conclusionsIn this first prospective study, [

Indexed as

DihydroxyphenylalanineNeuroendocrine TumorsPositron-Emission TomographyAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedRadiopharmaceuticalsDihydroxyphenylalaninefluorodopa F 18Radiopharmaceuticals[18F]DOPA[18F]SiTATENeuroendocrine tumor

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.